Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy: A switch study

Xiaohong Wang, Robert Savage, Andrey Borisov, Jill Rosenberg, Bobbi Woolwine, Melanie Tucker, Roberta May, Jacqueline Feldman, Charles B. Nemeroff, Andrew H. Miller

Research output: Contribution to journalArticlepeer-review

21 Scopus citations


The objective of the study was to examine whether patients with schizophrenia who were judged to be stable on long-term treatment with conventional antipsychotic medications would further benefit from a switch to an atypical antipsychotic drug. Thirty-six subjects with schizophrenia spectrum disorder, on conventional antipsychotic medication therapy for at least 2 years, were randomized in double-blind fashion to risperidone versus olanzapine. Patients were titrated up to 6 mg risperidone or 15 mg olanzapine as tolerated, followed by tapering and discontinuation of conventional antipsychotic medication. Atypical antipsychotic agents were then administered alone (monotherapy) for 12 weeks. Efficacy and tolerability were assessed using the Positive and Negative Syndrome Scale (PANSS), Clinical Global Impression Scale, and Simpson Angus Scale. Body weight was measured at each visit. Both treatment groups exhibited marked and similar improvement in the total PANSS score from baseline to study endpoint (22 weeks) [risperidone: baseline = 59.3 (SE 3.1), 22 weeks = 44.3 (SE 2.3) (p < 0.001); olanzapine: baseline = 55.9 (SE 3.3), 22 weeks = 46.9 (SE 3.2) (p < 0.001). Both groups also exhibited significant reductions in PANSS factor scores for positive and negative symptoms and disorganized thoughts. Only risperidone-treated patients exhibited significant decreases in uncontrolled hostility/excitement and anxiety and depression. Of note, while positive factor scores exhibited the majority of change within the first 10 weeks, negative factor scores continued to decline significantly in both treatment groups throughout the study. Tolerability assessments did not differ between groups. The results indicate that both atypical antipsychotic medications provided significant additional improvement in symptom severity in patients with schizophrenia previously on conventional antipsychotic agents.

Original languageEnglish (US)
Pages (from-to)669-676
Number of pages8
JournalJournal of Psychiatric Research
Issue number7
StatePublished - Oct 2006
Externally publishedYes


  • Atypical antipsychotic medication
  • Olanzapine
  • Psychopharmacology
  • Randomized clinical trial
  • Risperidone
  • Schizophrenia

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry
  • Psychology(all)


Dive into the research topics of 'Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy: A switch study'. Together they form a unique fingerprint.

Cite this